arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

CG Oncology, Inc.

CGON

$75.11 ▲ +0.38 (+0.51%) at close

14 Visible periods

26 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Weak

Bullish

auto_awesome

Analytical Summary

CG Oncology, Inc. shows strong fundamentals with top-quartile Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $6.3B

Dividend Yield —

Revenue Growth 1982.7%

Op. Margin —

ROIC -4.8% ↗

FCF / Share $-0.68

Trailing P/E —

Price / Book 6.1x

FCF Yield —

Debt / Equity 0.00

info Valuation on last close. End-of-day price, Aug 7, 2026.

14-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$1.08M

↑ +1982.7% —

Net Income Profit after all expenses

$-60.20M

↓ -74.7% —

FCF / Share Free cash flow per share

$-0.68

↓ -76.2% —

Long-Term Debt Long-term obligations

$3.00M

— 0.0% —

trending_up

Bullish Indicators

Debt to EquityDebt to Equity is in the top quartile (lower is better)

warning

Bearish Risks

No bearish risks detected.

Health Breakdown

Returns

Financial Health ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Revenue Growth YoY (%)	1982.7% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+24684%)	—	3774.4% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+47080%)	N/M	-90.2% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1227%)	—	377.8% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+4622%)	—	172.7% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+2059%)	—	—	—	—	—
EPS Growth YoY (%)	-57.8% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-6.3% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-90.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-92.9% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-25.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	89.3% Excellent → Excellent Stable Year-over-year change in earnings per share Optimal: > 10%	92.5% Excellent → Excellent Stable Year-over-year change in earnings per share Optimal: > 10%	92.9% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	88.8% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—
Net Income Growth YoY (%)	-74.7% Weak ↑ Weak Improving Year-over-year change in net income	-29.9% Weak ↑ Weak Improving Year-over-year change in net income	-103.4% Weak → Weak Stable Year-over-year change in net income	-103.4% Weak ↓ Weak Declining Year-over-year change in net income	-103.5% Weak ↓ Weak Declining Year-over-year change in net income	-92.1% Weak → Weak Stable Year-over-year change in net income	-95.3% Weak → Weak Stable Year-over-year change in net income	-95.3% Weak Weak Year-over-year change in net income	-95.4% Weak Weak Year-over-year change in net income	—	—	—	—	—
FCF Growth YoY (%)	-76.2% Weak Weak Year-over-year change in free cash flow	—	—	—	30.5% Excellent Excellent Year-over-year change in free cash flow	—	—	—	73.3% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—
Revenue CAGR 3Y (%)	77.4% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
FCF / Net Income (x)	0.95x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.88x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.13x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.81x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.85x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.66x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	1.54x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.88x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.41x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	1.24x Good Good Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Return on Invested Capital (%)	-4.8% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-5.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-5.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-5.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-4.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-4.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-4.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-3.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-3.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	12.4% Good ↑ Good Improving Return earned on debt + equity capital invested Optimal: > 10%	10.3% Good ↑ Good Improving Return earned on debt + equity capital invested Optimal: > 10%	10.0% Fair Fair Return earned on debt + equity capital invested Optimal: > 10%	8.9% Fair Fair Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-5.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-6.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-7.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-6.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-5.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-5.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-5.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-4.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	-3.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—	—
Return on Common Equity (%) (%)	-5.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-137%)	-5.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-137%)	-5.0% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-133%)	-5.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-134%)	-4.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-133%)	-4.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-129%)	-3.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-121%)	-3.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-120%)	-3.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-120%)	13.4% Fair ↑ Fair Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-10%)	8.1% Caution ↓ Caution Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-46%)	8.9% Caution Caution Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-41%)	10.1% Fair Fair Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-33%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Debt to Equity (x)	0.00x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-99%)	0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-99%)	—	—	0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	—	—	—	—	—	—	—	—
Interest Coverage (x)	-1412.53x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—	—	—	—	—	—	—	-117.39x Weak Weak Operating income divided by interest expense Optimal: > 5x	-35.87x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-30.70M	$-29.49M	$-42.15M	$-14.62M	$-41.47M	$-257.07M	$-43.41M	$-25.16M	$-77.47M	—	—	—	—	—
Debt / EBITDA (x)	-0.05x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.06x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.06x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	0.00x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—	—	—	—	—

📊 What does each share earn? 6 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Revenue per Share (USD)	$0.01	—	$0.02	$0.00	$0.00	—	$0.00	$0.00	$0.01	—	$0.00	$0.00	$0.05	—
Basic EPS, GAAP (USD)	$-0.71	$-0.51	$-0.57	$-0.54	$-0.45	$-0.48	$-0.30	$-0.28	$-0.36	$-4.47	$-4.00	$-3.93	$-3.22	—
Free Cash Flow per Share (USD)	$-0.68	—	$-0.51	$-0.37	$-0.38	—	—	—	$-0.55	—	$-2.80	$-2.75	$-2.07	—
Book Value per Share (USD)	$12.41	$9.33	$8.78	$8.79	$9.25	$9.63	$7.95	$8.29	$8.54	—	$-24.55	$-24.85	$-22.34	—
Tangible Book Value per Share (USD)	$12.29	$9.20	$8.62	$8.79	$9.25	$9.63	$7.95	$8.29	$8.54	—	$-24.55	$-24.85	$-22.34	—
Basic Weighted Avg Shares (shares)	84.52M	—	76.73M	76.23M	76.19M	—	67.14M	66.65M	47.06M	—	4.38M	3.92M	3.86M	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Working Capital (USD)	$1.07B	$728.64M	$665.26M	$642.65M	$678.55M	$732.84M	$536.45M	$552.01M	$568.63M	—	—	—	—	—
LT Debt (USD)	$3.00M	$3.00M	$3.00M	—	—	$0.00	—	—	—	—	—	—	—	—
Total Equity (USD)	$1.09B	$752.60M	$687.64M	$670.36M	$704.76M	$733.38M	$536.77M	$552.36M	$568.94M	$-123.10M	$-107.58M	$-97.39M	$-86.11M	$-77.69M

📋 What is driving earnings? 4 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Sales/Revenue/Turnover (USD)	$1.08M	—	$1.67M	$0.00	$52.00K	—	$43.00K	$111.00K	$529.00K	—	$9.00K	$0.00	$194.00K	—
Depreciation Expense (USD)	$841.00K	$849.00K	$416.00K	$156.00K	$24.00K	$0.00	—	—	$4.00K	$4.00K	$5.00K	$4.00K	$4.00K	—
Net Income, GAAP (USD)	$-60.20M	$-41.31M	$-34.45M	$-34.45M	$-34.45M	$-31.80M	$-16.93M	$-16.93M	$-16.93M	$-16.55M	$-8.67M	$-8.67M	$-8.67M	—
Operating Cash Flow (USD)	$-56.94M	$-36.22M	$-38.89M	$-27.96M	$-29.28M	$-20.66M	—	—	$-26.01M	$-14.64M	$-12.26M	$-10.79M	$-7.99M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 4 years · 14 quarters

CG Oncology, Inc.

Analytical Summary

14-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare CGON with peers